Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 674.95

+3.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biotechwantabe who wrote (2912)	4/25/2020 6:13:24 AM
From: nigel bates	Read Replies (1) of 3557

If it’s not a foolish question, how easy will it be to deliver sufficient quantity of the MAb to the lungs, if it’s administered intravenously ? While there might be some benefits in protecting heart and kidneys, won’t it at the very least be quite expensive (and difficult to produce enough quantity quickly for widespread use) ? Along those lines, does anyone know why Sanofi abandoned their inhaled anti-RSV nanobody ? Was it for commercial or technical reasons ? Had that worked, it could have been an interesting platform for developing a treatment. link.springer.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next